Merck & Co. (MRK)
(Delayed Data from NYSE)
$104.23 USD
+0.25 (0.24%)
Updated Oct 28, 2024 04:02 PM ET
After-Market: $104.26 +0.03 (0.03%) 6:50 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$104.23 USD
+0.25 (0.24%)
Updated Oct 28, 2024 04:02 PM ET
After-Market: $104.26 +0.03 (0.03%) 6:50 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
No Econ Data, but Big Biopharma News
by Mark Vickery
Merck, Gilead and Lilly make progress on an otherwise slow news day.
Pharma Stock Roundup: AZN & PFE's Coronavirus Vaccine Updates & FDA Approvals
by Kinjel Shah
AstraZeneca (AZN) halts coronavirus vaccine study. FDA approves Roche (RHHBY) and Glaxo's (GSK) medicines.
Zacks Market Edge Highlights: MRK, ABBV, PXD, VBR and VIOO
by Zacks Equity Research
Zacks Market Edge Highlights: MRK, ABBV, PXD, VBR and VIOO
Merck's Pneumococcal Vaccine Meets Goals in Late-Stage Studies
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $84.88 in the latest trading session, marking a +1.86% move from the prior day.
Generation X Investors: Deja Vu?
by Tracey Ryniec
Generation X investors came of age in the dot-com boom when Microsoft and other tech titans hit new highs. Now, in 2020, it's happening again.
Merck Announces Detailed Data on Late-Stage Cough Candidate
by Zacks Equity Research
Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.
CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge
by Kinjel Shah
The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.
Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study
by Kinjel Shah
Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.
Here's Why AstraZeneca (AZN) Stock is Up This Year So Far
by Zacks Equity Research
AstraZeneca's (AZN) shares are up this year mainly due to rapid progress in its efforts to make a vaccine to treat COVID-19 as well as other positive pipeline and regulatory updates.
Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity
by Zacks Equity Research
Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.
J&J to Stop Development of Influenza Candidate Pimodivir
by Zacks Equity Research
Johnson & Johnson (JNJ) to halt the development of pimodivir, an investigational antiviral treatment of influenza A infection.
Innoviva (INVA) in Focus: Stock Moves 7% Higher
by Zacks Equity Research
Innoviva (INVA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Dow Jones Tops 29,000: Will ETFs & Stocks Rally in September?
by Sanghamitra Saha
The Dow jumped above 29,000 for the first time since February on Sep 2 on low rates and vaccine hopes.
Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg
by Zacks Equity Research
Bristol Myers' (BMY) Onureg becomes the first and only FDA-approved continued AML therapy for patients in remission.
AstraZeneca's Imfinzi Gets EU Approval for First-Line SCLC
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi gets approval in Europe to treat extensive-stage small cell lung cancer.
The Zacks Analyst Blog Highlights: CRM, MRK, T, NKE and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CRM, MRK, T, NKE and GSK
Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Bayer Submits Application for Heart Failure Drug in China
by Zacks Equity Research
Bayer (BAYRY) submits a regulatory application seeking approval for vericiguat to treat patients with symptomatic chronic heart failure in China.
Pharma Stock Roundup: AZN's Coronavirus Antibody Combo Study, & Other Updates
by Kinjel Shah
AstraZeneca (AZN) begins dosing in phase I study on antibody cocktail therapy to treat COVID-19. Glaxo's (GSK) Blenrep gets approval in Europe.
Top Analyst Reports for Salesforce, Merck & AT&T
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including salesforce.com (CRM), Merck Co. (MRK) and AT&T (T).
Why Is Merck (MRK) Up 8.4% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Apple, NIKE, Walt Disney, PG and MRK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, NIKE, Walt Disney, PG and MRK
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
Merck's Keytruda Gets Approval for Esophageal Cancer in Japan
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval in Japan as second-line treatment for esophageal squamous cell carcinoma. A new dosing regimen also receives approval in the country.